Contribute Try STAT+ Today

WASHINGTON — A top Republican lawmaker on Wednesday hinted that the Senate stagnation of a bipartisan drug pricing bill has a high-profile culprit: President Trump.

The comments mark the second time in as many months that Sen. Chuck Grassley (R-Iowa), the chairman of the Senate Finance Committee, has suggested Republican Party leadership must act more forcefully on the issue of drug pricing. While the White House has formally endorsed the bill Grassley authored with Sen. Ron Wyden (D-Ore.), Trump has not personally pushed it with nearly the same enthusiasm that he displayed for other GOP health care efforts, like the party’s failed attempt to repeal the Affordable Care Act in 2017.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.